$VIVS

VivoSim Labs (VIVS) welcomes FDA's updated regulations allowing greater use of non-animal testing methods. The rule replaces 'animal tests' with 'nonclinical tests,' benefiting VivoSim's 3D human cellular models. VivoSim's models can identify drug safety risks earlier, reducing development costs. The company expects accelerated adoption of its NAM models following the FDA's roadmap.

VivoSim (VIVS) reported its NAMkind(TM) Liver model achieved 91% predictive accuracy, 90% sensitivity, and 95% specificity in drug-induced liver injury tests. Its VitroSense(TM) AI platform showed up to 96% accuracy in predicting drug-induced diarrhea. The company plans to develop a rat liver model to bridge animal and human data, aiming for regulatory and pharmaceutical adoption. Key milestones include FDA qualification and broader industry use.

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 30, 2026, VivoSim Labs, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting

VivoSim Labs (NASDAQ: VIVS) presented data at EUROTOX 2026 showing its NAMkind™ platforms can predict drug toxicity in liver and gastrointestinal systems for small molecules and ADCs. The data ranked clinical safety risks and distinguished payload- and linker-dependent toxicities in ADCs, positioning VivoSim in the growing market for human-relevant predictive toxicology.

VivoSim Labs (VIVS) presented data at EUROTOX 2026 showing its NAMkind™ platforms can predict drug toxicity in liver and gut models. The liver platform maintains viability for 28 days, while intestinal models preserve barrier function for three weeks. Studies ranked safety risks for small molecules and differentiated ADC toxicities, with trastuzumab deruxtecan showing higher hepatotoxicity. The stock declined 4.18% post-announcement, trading at $0.26 with heavy volume.

VivoSim Labs (VIVS) is developing a rat liver model to complement its human liver model, aiming to improve drug toxicity predictions. This could help pharma companies make earlier decisions on drug candidates, potentially expanding VIVS's NAMkind(TM) platform's use. The FDA's push for human-relevant testing may provide a favorable backdrop. VIVS expects 500%+ fiscal 2027 revenue growth from its NAM-based business.

GoPro (GPRO) to merge with Starman Optical for $285M, expanding into AI data centers. Fly-E (FLYE) reports $19.1M revenue, growing in electric mobility. Cellyan (HKPD) operates in cross-border pharmaceutical e-commerce. VivoSim (VIVS) has $10.1M cash, aided by a $5M milestone from Eli Lilly (LLY).

Lialin Tony Serge (Chief Commercial Officer) purchased 10,000 shares of VivoSim Labs, INC. (VIVS) at $0.28 on 2026-08-31.

VivoSim Labs (Nasdaq: VIVS) plans to develop a rat liver model to complement its human liver platform, aiming to help pharma companies distinguish rat-specific toxicity from human risks. The model is designed to validate compounds with known toxicity differences between rats and humans, potentially broadening the utility of its NAMkind™ platform. The company believes this addition could strengthen its position in liver toxicology and accelerate commercial growth.

Investor interest is growing in four small-cap stocks: VivoSim Labs (VIVS), IGC Pharma (IGC), Algorhythm Holdings (RIME), and Xiao-I (AIXI). VIVS reported a $5M milestone payment from Eli Lilly and targets 500%+ revenue growth. IGC beat Q2 estimates and expects Alzheimer's trial results in Q4. RIME is exploring strategic alternatives for its SemiCab AI logistics business. AIXI focuses on enterprise AI solutions. All four stocks trade near $0.30.